GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Shiller PE Ratio

Jazz Pharmaceuticals (Jazz Pharmaceuticals) Shiller PE Ratio

: 24.36 (As of Today)
View and export this data going back to 2007. Start your Free Trial

As of today (2024-04-19), Jazz Pharmaceuticals's current share price is $109.855. Jazz Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $4.51. Jazz Pharmaceuticals's Shiller PE Ratio for today is 24.36.

The historical rank and industry rank for Jazz Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

JAZZ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.46   Med: 32.05   Max: 3774.25
Current: 24.36

During the past years, Jazz Pharmaceuticals's highest Shiller PE Ratio was 3774.25. The lowest was 19.46. And the median was 32.05.

JAZZ's Shiller PE Ratio is ranked better than
59.72% of 144 companies
in the Biotechnology industry
Industry Median: 32.26 vs JAZZ: 24.36

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $4.51 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Jazz Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.22 31.55 27.26 38.40 27.28

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.40 34.45 28.24 28.79 27.28

Competitive Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Shiller PE Ratio falls into.



Jazz Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Jazz Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=109.855/4.51
=24.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.42/120.1096*120.1096
=1.420

Current CPI (Dec. 2023) = 120.1096.

Jazz Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.580 100.573 -1.887
201406 0.700 100.773 0.834
201409 0.410 100.474 0.490
201412 1.300 99.576 1.568
201503 1.120 99.975 1.346
201506 1.400 100.573 1.672
201509 1.390 100.274 1.665
201512 1.320 99.676 1.591
201603 1.210 99.676 1.458
201606 1.850 101.072 2.198
201609 1.450 100.274 1.737
201612 1.910 99.676 2.302
201703 1.410 100.374 1.687
201706 1.720 100.673 2.052
201709 1.030 100.474 1.231
201712 3.790 100.075 4.549
201803 0.750 100.573 0.896
201806 1.500 101.072 1.783
201809 2.410 101.371 2.856
201812 2.640 100.773 3.147
201903 1.470 101.670 1.737
201906 4.560 102.168 5.361
201909 1.780 102.268 2.091
201912 1.290 102.068 1.518
202003 -2.820 102.367 -3.309
202006 2.060 101.769 2.431
202009 2.640 101.072 3.137
202012 2.330 101.072 2.769
202103 2.090 102.367 2.452
202106 -6.110 103.364 -7.100
202109 -0.860 104.859 -0.985
202112 -0.570 106.653 -0.642
202203 0.030 109.245 0.033
202206 0.550 112.734 0.586
202209 -0.310 113.431 -0.328
202212 -3.820 115.425 -3.975
202303 1.040 117.618 1.062
202306 1.520 119.611 1.526
202309 2.140 120.708 2.129
202312 1.420 120.110 1.420

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jazz Pharmaceuticals  (NAS:JAZZ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Jazz Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (Jazz Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Executives
Jennifer E. Cook director C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Neena M Patil officer: SVP, General Counsel JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Patricia Carr officer: VP, Finance& PAO JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Heather Ann Mcsharry director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Peter Gray director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan director HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe director C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603
Mary Elizabeth Henderson officer: SVP, Technical Operations 3170 PORTER DRIVE, PALO ALTO CA 94304
Renee D Gala officer: EVP & CFO 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kim Sablich officer: EVP & GM, North America C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005